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rare diseases, consideration of alternative acceptance criteria for
public reimbursement /health service provision may be required.
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OBJECTIVES: Estimation of cost-effectiveness of health tech-
nologies tends to focus on the time period at or around launch,
to fulﬁll the growing requirements of reimbursement or market
access agencies. This study reviews the factors which inﬂuence
cost-effectiveness over time and demonstrates the temporal
impact on cost-effectiveness using a number of case-studies. The
implications for decision making and market access are dis-
cussed. METHODS: A review of the factors that may inﬂuence
cost-effectiveness over time and methodological approaches used
to address these was conducted. Earlier analytical frameworks
of studies from the 1990s in the ﬁelds of motor airbags,
implantable cardiac deﬁbrillators, statins, renal dialysis and
hearing aids were revisited to re-estimate the cost-effectiveness.
For example, parameters of an economic evaluation conducted
in 1990 for erythropoetin were updated to 2004 values using a
recent systematic review of clinical evidence together with
revised unit costs and expert clinical opinion for resource utili-
sation. RESULTS: For the majority of case-studies examined,
there was a trend for the reduction in cost-effectiveness ratios
over time—e.g. for erythropoetin, the base-case cost per QALY
decreased ten-fold over a 14 year period (£216,906 to £21,547).
Signiﬁcant factors included unit costs, dosage, utility gains 
and revised discounted rates. CONCLUSIONS: The timing of
economic evaluation is critical in the estimation of cost-
effectiveness. Production of this evidence may often be the ﬁrst
time that the conceptual framework of economic analysis has
been applied to the technology, despite suggestions that eco-
nomic evaluation should be used iteratively throughout the
product life-cycle. This study has demonstrated that whilst 
there is a need for economic evaluation results to be timely to
aid decision-making (i.e. at or around launch), it is important
that the analysis is updated and reviewed periodically to assess
whether cost-effectiveness has changed sufﬁciently to justify
modifying the original decision.
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OBJECTIVES: To compare the quality of the health economic
material submitted to the Swedish Pharmaceutical Beneﬁts Board
and the Finnish Pharmaceuticals Pricing Board as part of 
the application for reimbursement for new pharmaceuticals.
METHODS: The health economic evaluations were reviewed in
each country against two checklists, marking each question
Yes/No/Not Applicable. The checklists used were: 1) the respec-
tive national Guidelines transformed into yes or no questions,
and 2) the QHES check list, a validated instrument, was also
used to provide a common comparator. The central estimate of
cost effectiveness was collected (cost per QALY) as well as
whether the application was accepted or rejected in each country.
RESULTS: The Swedish scores range from 0.24 to 0.87 and on
the QHES from 0.09 to 1, with a mean quality of 0.61 and 0.67
respectively. The Finnish scores range from 0.58 to 0.96 and on
the QHES from 0.28 to 0.84, with a mean quality of 0.76 and
0.62 respectively. The correlation between the respective national
guidelines and the QHES scores is modest (approx. 0.7 both in
Sweden and in Finland). This is mostly due to country speciﬁc
criteria. There was a low observed correlation between quality
score and acceptance in Sweden and also in Finland. Likewise,
the correlation between cost per QALY and decision to
accept/reject is low to medium. CONCLUSIONS: Health eco-
nomic material as part of applications to reimbursement agen-
cies varies widely in quality. There are differences even for the
same product in the two countries. Secondly, due to the relatively
small number of applications studied and the even fewer rejec-
tions, it is difﬁcult to draw ﬁrm conclusions regarding the value
the pricing authorities studied place on a QALY.
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OBJECTIVE: Medicare reform legislation requires the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs and to recommend whether
payment for handling costs of Part B speciﬁed outpatient drugs
should be made under the Medicare Hospital Outpatient
Prospective Payment System (OPPS). This study explores the
MedPAC approach to pharmacy departmental costs and poten-
tial reimbursement implications. METHODS: The MedPAC
rationale and recommendations were deconstructed, evaluated,
and compared to data about pharmacy operations obtained from
two studies. The ﬁrst study collected data from on-site observa-
tions of infusion therapy and related pharmacy activities in 24
hospital outpatient departments (HOPDs) located in 19 states.
A subsequent telephone survey gathered information about
stafﬁng and workﬂow from 30 other hospital pharmacy direc-
tors located in 16 states and the District of Columbia. RESULTS:
The MedPAC report places pharmacy costs into ﬁve categories;
concludes that hospitals can estimate these costs; and recom-
mends that hospitals develop and submit charges for a new set
of handling fee APCs. Findings from the comparative on-site
observations and telephone survey, however, reveal that signiﬁ-
cant portions of certain costs are not charged to the pharmacy.
For example, 69.1% of respondents had information systems
costs charged outside the department while 34.5% reported their
entire information systems costs charged elsewhere. Likewise,
73.3% of respondents reported reimbursement, chargemaster,
clerical and transport staff utilized by the pharmacy department
but not charged to the department. Such disparities in depart-
mental costing will signiﬁcantly hinder the uniform interpreta-
tion of costs assumed by MedPAC. CONCLUSIONS: Payment
methods in 2006 for handling costs of Part B separately paid
drugs will be derived in large part from the MedPAC recom-
mendations. If the payment methodology does not take existing
variations in recording pharmacy expense outside the depart-
ment, hospital providers may well be underpaid for handling
costs in 2006.
PHP43
IMPACT OF PHARMACEUTICAL POLICIES ON
PROMOTIONAL TARGETED DRUGS
Layton MR1, Chadbunchachai S1,Thinkhamrop B1,
Tangcharoensathien V2,Wertheimer AI3
1Khon Kaen University, Khon Kaen,Thailand; 2International Health
Policy Program, Nonthaburi,Thailand; 3Temple University, Philadelphia,
PA, USA
A194 Abstracts
OBJECTIVES: To explore the trends in physicians’ prescribing
of promotional targeted drugs (PTD) in two categories—Statins
and COX-2 inhibitors, before and after implementing the phar-
maceutical policies which included the National Essential Drug
List (NEDL), the health beneﬁt schemes, and the regulation 
of the hospital Pharmacy & Therapeutic Committee (PTC).
METHODS: Electronic outpatient prescription records of the
PTDs and the established drugs in the same category at a teach-
ing hospital were compared. Data on how and when the PTD
got approved by the PTC including the prescribing restrictions
were also assembled. A time series analysis of prescription data
for each drug was constructed and marked for any known phe-
nomena during 1998–2004. RESULTS: The highly promoted
drugs in both groups showed signiﬁcant increases in drug uses
after the implementation of pharmaceutical policies especially 
if the drug was listed in the NEDL. The majority of the drug
costs were acquired by cash payment and the price for expensive
drugs varied between 5–10 times that of the alternatives in the
same category. While the sales shares for expensive drugs
increased enormously, the trend decreased drastically for the
alternative drugs. Among the health schemes, the Civil Servants
Medical Beneﬁt Scheme beneﬁciaries were likely get expensive
drugs than others. CONCLUSIONS: This exploratory study
reveals the different types of pharmaceutical policies that can
have an impact on the trend of physicians’ PTD prescribing. The
ﬁndings call for further in-depth investigation of critical factors
inﬂuencing physician prescribing behavior of PTDs in order to
curb the escalating drug cost and promote rational drug use in
the country.
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OBJECTIVE: The purpose of this evaluation was to identify the
types of interventions made by clinical pharmacists, determine
the cost avoidance of pharmacist interventions and incorporate
the information into a new system at Grady Health System.
METHODS: Two phases were required to characterize the type,
cost avoidance and total number of daily documented interven-
tions made by clinical pharmacists from April 1998 to July 2003.
A third phase was used to evaluate interventions made from June
2004–May 2005. Interventions were classiﬁed by the interven-
tion type, assigned cost avoidance and the assigned a probabil-
ity of likely occurrence of an event without intervention. Data
was collected in phase two of the evaluation to determine the
average documented daily interventions per clinical pharmacist
and the total cost avoidance of clinical pharmacist interventions
for the department. RESULTS: A total of 1,871 (29.6%) of
6,311 documented interventions were reviewed. There was an
average of 4.9 interventions per adjusted workday documented.
The average cost avoidance of a documented intervention 
was $288. The daily adjusted work day cost avoidance was
$1411.20 or an annual cost avoidance of $338,688 for the 64
month time period. If extrapolated to the entire data set, the cost
avoidance would be $1,798,567. In the second phase of the
project, the average number of daily interventions documented
by a clinical pharmacist was 5.5 (SD ± 1.2) resulting in an extrap-
olated annual cost avoidance of $380,160 per clinical pharma-
cist. In the ﬁnal phase of the project, the average number of
interventions increased to 26.2/day or a total of 9,552 pharma-
cist interventions. The cost to the health system is $128,941 
in pharmacist salary dollars with cost avoidance savings of
$2,037,863. CONCLUSION: The return on investment of the
system was $16 for every dollar spent on clinical pharmacy ser-
vices. Each intervention saves $213 for the health system.
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French GPs are increasing reluctant to dispense medical services
in OOH because of security concerns and lack of economic
incentives. In order to motivate GPs to participate to OOH care,
experimental MMGs have been set up. A medical ofﬁce is shared
by GPs on duty to provide medical services in predetermined
time schedules. Referrals to MMG are determined by emergency
dispatching centres (C15) and/or hospital emergency depart-
ments (HED). GPs receive a forfeit, adjusted with effectively dis-
pensed visits. Facilities are secured. OBJECTIVE: To assess the
5 MMG activity in comparison to HED, C15 and other home
cares and patients and professionals satisfaction. METHODS:
“Before-after” assessment month 2 to 6 after MMGs were set
up and reproduced at month 14 to 18. Quantitative data were
collected from MMGs, “C15”, HED and health insurance.
Questionnaires were submitted to patients (visiting/calling HED,
“C15”, GPs practices or MMG, n = 537), and professionals (GPs
involved in MMGs, HED and C15 professionals n = 389).
RESULTS: Half of the practitioners in MMGs area participated.
Most patients (95%) were in need of primary care. On weekend
days, number of visits to MMG were approximately equivalent
or superior to an ofﬁce based GP (22), but on weekdays
(8pm–12pm) average number of visits was low (<4). Patients and
GPs were satisﬁed with services. MMGs however can not meet
all OOH needs, particularly home visits. Although they differ in
organisation, there is room for optimization for all MMGs. Pro-
fessionals are unable to deﬁne precisely OOH primary care, and
communication to patients, highly desirable, is not yet harmo-
nized. CONCLUSION: MMG should be encouraged but provide
only partial response, as a global approach including home visits
is needed.
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OBJECTIVE: To propose a deﬁnition of compliance/adherence
and persistence which would be widely agreed and useful in pro-
viding consistency for clinical, health policy and clinical practice
research. METHODS: The “Issues and Deﬁnitions Working
Group” of the Medication Compliance Special Interest Group
undertook to review deﬁnitions that could be used for medica-
tion compliance/adherence and persistence. Broad deﬁnitions
were presented at an ISPOR workshop in 2003 and revised
accordingly. These deﬁnitions were then placed on the ISPOR
website and all members were given an opportunity to comment
and vote on deﬁnitions in December 2004. Although consensus
was reached for the compliance and persistence deﬁnitions, many
key issues related to these deﬁnitions required resolution. At the
Annual Meeting 2005, a workshop was held to discuss the issues
